{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Abuknesha NR"],"funding":["NIA NIH HHS","NHLBI NIH HHS"],"pubmed_abstract":["Background
Recent meta-analyses of randomized controlled trials (RCTs) have raised concerns that treatment with omega-3 fatty acids may increase risk of atrial fibrillation (AF). However, these meta-analyses included at most eight trials. The aim of this current meta-analysis was to expand the search by including other eligible omega-3 RCTs with AF incidence data, incorporating both published and unpublished data.Methods
Eligible studies were RCTs investigating daily doses of ≥500 mg/d of docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA). Additional inclusion criteria included ≥12 months treatment with EPA/DHA, participants ≥ 50 years of age, and where possible, the absence of known AF/atrial flutter at baseline. The primary outcome was occurrence of new-onset A"],"journal":["medRxiv : the preprint server for health sciences"],"pagination":["2025.12.14.25342167"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12723971"],"repository":["biostudies-literature"],"pubmed_title":["Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 34 Trials including 114,326 Individuals."],"pmcid":["PMC12723971"],"funding_grant_id":["T32 HL125232","U19 AG010483"],"pubmed_authors":["Chew EY","Lan TH","Schoenfeld DA","Welty FK","Su KP","Tintle NL","Harris WS","Mengelberg A","Yusuf S","Van Hulle CA","Abuknesha NR","Lin Y","Vauzour D","Cohen NJ","Liddell A","Budoff MJ","Sanders TAB","Fezeu LK","Galan P","Burns NR","Aisen PS","Bischoff-Ferrari HA","van Dyck CH","Cardenas CA","Qian HZ","Asbeutah AAA","O'Keefe JH","Qian F","Weber C","Aronson WJ","Albert CM","Carlsson CM","Hull MA","Sun Y","Lin PY","Quinn JF","Minihane AM","Sprange K","Wittert G","Scholey A"],"additional_accession":[]},"is_claimable":false,"name":"Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 34 Trials including 114,326 Individuals.","description":"Background
Recent meta-analyses of randomized controlled trials (RCTs) have raised concerns that treatment with omega-3 fatty acids may increase risk of atrial fibrillation (AF). However, these meta-analyses included at most eight trials. The aim of this current meta-analysis was to expand the search by including other eligible omega-3 RCTs with AF incidence data, incorporating both published and unpublished data.Methods
Eligible studies were RCTs investigating daily doses of ≥500 mg/d of docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA). Additional inclusion criteria included ≥12 months treatment with EPA/DHA, participants ≥ 50 years of age, and where possible, the absence of known AF/atrial flutter at baseline. The primary outcome was occurrence of new-onset A","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-07-05T03:11:48.132Z","creation":"2026-07-05T03:08:32.154Z"},"accession":"S-EPMC12723971","cross_references":{"pubmed":["41445624"],"doi":["10.64898/2025.12.14.25342167"]}}